On May 20, 2025, HC Wainwright & Co., represented by analyst Raghuram Selvaraju, reiterated its "Buy" rating for Fennec Pharmaceuticals (FENC, Financial). This reaffirmation reflects continued confidence in the company's market position and potential growth trajectory. The analyst did not alter the existing rating, maintaining it at "Buy," consistent with their previous stance.
In addition to the rating, HC Wainwright & Co. has maintained the price target for Fennec Pharmaceuticals (FENC, Financial) at USD 13.00. This price target remains unchanged from prior evaluations, indicating a stable outlook based on current market conditions and company performance.
Fennec Pharmaceuticals (FENC, Financial) is currently trading on the NASDAQ, and this maintained price target reflects HC Wainwright & Co.'s forecast on the company's stock potential. Investors may view this consistent rating and price target as an indication of confidence in the firm's future prospects.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Fennec Pharmaceuticals Inc (FENC, Financial) is $12.80 with a high estimate of $15.00 and a low estimate of $10.00. The average target implies an upside of 67.32% from the current price of $7.65. More detailed estimate data can be found on the Fennec Pharmaceuticals Inc (FENC) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, Fennec Pharmaceuticals Inc's (FENC, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
